NCT00607451View on ClinicalTrials.gov

Safety, Tolerability, PK and PD Study of Neu-120 in the Treatment of Levodopa-induced Dyskinesia

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

March 31, 2008

Primary Completion Date

August 27, 2016

Study Completion Date

August 27, 2016

Conditions
Levodopa-induced Dyskinesia
Interventions
DRUG

Neu-120

Capsules of 300, 900 and 2700mg; administered as a single dose with a one week washout between each administration.

Trial Locations (1)

69710

Neurim Pharmaceuticals Ltd., Tel Aviv

Sponsors
All Listed Sponsors
lead

Neurim Pharmaceuticals Ltd.

INDUSTRY

NCT00607451 - Safety, Tolerability, PK and PD Study of Neu-120 in the Treatment of Levodopa-induced Dyskinesia | Biotech Hunter | Biotech Hunter